Expert Outlook: Silk Road Medical Through The Eyes Of 5 Analysts

Throughout the last three months, 5 analysts have evaluated Silk Road Medical SILK, offering a diverse set of opinions from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.0, a high estimate of $20.00, and a low estimate of $8.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 67.3%.

Exploring Analyst Ratings: An In-Depth Overview

The analysis of recent analyst actions sheds light on the perception of Silk Road Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Silk Road Medical. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Silk Road Medical compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Silk Road Medical's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Silk Road Medical's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Silk Road Medical analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Silk Road Medical

Silk Road Medical Inc is a medical device company focused on reducing the risk of stroke and its devastating impact. The company has a new approach for the treatment of carotid artery disease called transcarotid artery revascularization, or TCAR, which it seeks to establish as the standard of care. TCAR relies on two novel concepts - minimally-invasive direct carotid access in the neck and high-rate blood flow reversal during the procedure to protect the brain - and combines novel endovascular techniques with fundamental surgical principles. TCAR using its portfolio of products has been clinically demonstrated to reduce the upfront morbidity and mortality risks commonly associated with carotid endarterectomy while maintaining a reduction in long-term stroke risk.

Breaking Down Silk Road Medical's Financial Performance

Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.

Revenue Growth: Silk Road Medical displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 18.89%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Silk Road Medical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -28.78% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Silk Road Medical's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -8.29%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Silk Road Medical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -4.88%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Silk Road Medical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.5.

Understanding the Relevance of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.